MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.schres.2014.07.015

Медицинская библиотека · Schizophrenia research · 2014

Antipsychotic switching versus augmentation among early non-responders to risperidone or olanzapine in acute-phase schizophrenia.

Hatta Kotaro, Otachi Taro, Fujita Kiyoshi, Morikawa Fumiyoshi, Ito Shin, Tomiyama Hirofumi, Abe Takayuki, Sudo Yasuhiko, Takebayashi Hiroshi, Yamashita Toru, Katayama Shigemasa, Nakase Reiko, Shirai Yutaka, Usui Chie, Nakamura Hiroyuki, Ito Hiroto, Hirata Toyoaki, Sawa Yutaka, JAST study group

СтатьяМногоцентровое исследованиеРандомизированное исследованиеПоддержка исследования: вне правительства СШАПеревод в очереди

Аннотация

PURPOSE: We examined whether augmentation with olanzapine would be superior to switching to olanzapine among early non-responders (ENRs) to risperidone, and whether augmentation with risperidone would be superior to switching to risperidone among ENRs to olanzapine. We performed a rater-blinded, randomized clinical trial at psychiatric emergency sites. Eligible patients were newly admitted patients with acute schizophrenia. ENRs to the initial antipsychotic (Clinical Global Impressions-Improvement Scale: ≥ 4 at 2 weeks) were allocated to receive either augmentation with or switching to the other antipsychotic (RIS+OLZ vs. RIS-OLZ; OLZ+RIS vs.

OLZ-RIS)

RESULTS

Sixty patients who completed 2 weeks of risperidone treatment were divided into 33 early responders (RIS-ER) and 27 ENRs (RIS+OLZ, n=14; RIS-OLZ, n=13). Although time to treatment discontinuation for any cause was significantly shorter in RIS+OLZ group (54.1 days [95% confidence interval, 41.3-67.0]) than in RIS-ER group (68.7 [61.2-76.2]; P=0.050), it was not significantly shorter in RIS-OLZ group (58.5 [43.1-73.9]) than in RIS-ER group (P=0.19). Sixty patients who completed 2 weeks of olanzapine treatment were divided into 36 early responders (OLZ-ER) and 24 ENRs (OLZ+RIS, n=11; OLZ-RIS, n=13). Although time to treatment discontinuation for any cause was significantly shorter in OLZ-RIS group (56.1days [40.7-71.5]) than in OLZ-ER group (74.9 [68.5-81.3]; P=0.008), it was not significantly shorter in OLZ+RIS group (64.6 [49.6-79.6]) than in OLZ-ER group (P=0.20).

CONCLUSION

Despite the lack of pharmacokinetic investigation of dose adequacy in this study, it is possible that switching to olanzapine among ENRs to risperidone might have a small advantage over augmentation with olanzapine, while augmentation with risperidone might have a small advantage over switching to risperidone among ENRs to olanzapine. Further research is required before it would be appropriate to modify routine practice in the direction of these findings.

Для цитирования: Hatta Kotaro, Otachi Taro, Fujita Kiyoshi, Morikawa Fumiyoshi, Ito Shin, Tomiyama Hirofumi, Abe Takayuki, Sudo Yasuhiko, Takebayashi Hiroshi, Yamashita Toru, Katayama Shigemasa, Nakase Reiko, Shirai Yutaka, Usui Chie, Nakamura Hiroyuki, Ito Hiroto, Hirata Toyoaki, Sawa Yutaka, JAST study group. Antipsychotic switching versus augmentation among early non-responders to risperidone or olanzapine in acute-phase schizophrenia.. Schizophrenia research. 2014. DOI: 10.1016/j.schres.2014.07.015.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.